Nitric oxide and the cardiopulmonary system

Current Opinion in Critical Care

Volumn 4, Issue 5, 1998, Pages 331-338

  Symeonides, Simon ^a   Balk, Robert A ^a   Dellinger, R Phillip ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0039413679     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-199810000-00011     Document Type: Article

References (65)

1. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU, et al.: Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987, 79:124-130.
2. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA: Interleukin-1 induces a shock like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988, 81:1162-1172.
3. Lincoln TM, Cornwall TL: Towards an understanding of the mechanism of action of cyclic AMP and cyclic GMP in smooth muscle relaxation. Blood Vessels 1991, 28:129-137.
4. Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991, 43:109-142.
5. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE: Tumor necrosis factor alpha and interleukin-1 beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996, 183:949-958.
6. Parker JL, Adams HR: Development of myocardial dysfunction in endotoxin shock. Am J Physiol 1985, 248:H818-H826.
7. Kumar A, Thota V, Kosuri R, Dee L, Olson J, Uretz E, Parrillo JE: Nitric oxide and cyclic GMP generation mediates human septic serum-induced in-vitro cardiomyocyte depression [abstract]. Chest 1993, 104:123.
8. Kumar A, Kosuri R, Kandula P, Olson J, Dee L, Uretz E, Parrillo JE: Interleukin-1-beta induced myocardial cell depression is mediated by nitric oxide generation [abstract]. Crit Care Med 1995, 23:A149.
9. Kumar A, Kosuri R, Thota V, Olson J, Dee L, Stolz U, el al.: Tumor necrosis factor induced myocardial cell depression is mediated by nitric oxide and cGMP generation. Circulation 1993, 88(suppl):1617.
10. Hare JM, Keaney JF, Balligand JL, Loscalzo J, Smith TW, Colucci WS: Role of nitric oxide in parasympathetic modulation of beta-adrenergic myocardial contractility in normal dogs. J Clin Invest 1995, 95:360-366.
11. Balligand JL, Kobzik L, Han X, Kaye DM, Belhassen L, O'Hara DS, et al.: Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J Biol Chem 1995, 270:14582-14586.
12. Kumar A, Thota V, Kosuri R, Kandula P, Olson J, Dee L, et al.: Tumor necrosis factor impairs epinephrine-stimulated cardiomyocyte contractility and cyclic AMP response through a nitric oxide-independent mechanism [abstract]. Crit Care Med 1995, 23:A148.
13. Chung MK, Gulick TS, Rotondo RE, Schrener GF, Lange LG: Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes: impairment of signal transduction. Circ Res 1990, 67:753-763.
14. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, et al.: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984, 100:483-490.
15. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W: A circulating myocardial depressant substance in humans with septic shock: septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell permformance. J Clin Invest 1985, 76:1539-1553.
16. Reilly JM, Cunnion RE, Burch-Whitman C, Parker MM, Shelhamer JH, Parrillo JE: A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic shock. Chest 1989, 95:1072-1080.
17. Fort S, Lewis MJ: Regulation of myocardial contractile performance by sodium nitroprusside in the isolated perfused heart of the ferret. Br J Pharmacol 1991, 102:351P.
18. Brady AJ, Warren JB, Poole-Wilson PA, Williams TJ, Harding SE: Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol 1993, 265:H176-H182.
19. Grocott-Mason R, Fort S, Lewis MJ, Shah AM: Myocardial relaxant effect of exogenous NO in isolated ejecting hearts. Am J Physiol 1994, 266:H1699-H1705.
20. Wahler GM, Dollinger SJ: Nitric oxide donor SIN-1 inhibits mammalian cardiac calcium current through cGMP-dependent protein kinase. Am J Physiol 1995, 268:C45-C54.
21. Levi RC, Alloatti G, Penna C, Gallo MP: Guanylate-cyclase-mediated inhibition of cardiac ICa by carbachol and sodium nitroprusside. Pflugers Arch 1994, 426:419-426.
22. Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T: Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci U S A 1993, 90:347-351.
23. Teule GJ, von Lingen A, Verwey von Veight MA, Kester AD, MacKaay RC, Bezemer PD, Thijis LG: Role of peripheral pooling in porcine Escherichia coli sepsis. Circ Shock 1984, 12:115-123.
24. Ochoa JB, Udekwu AO, Billiar TR, Curran RD, Cerra FB, Simmons RL, Peitzman AB: Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg 1991, 214:621-626.
25. Rosenberg RB, Broner CW, O'Dorisio MS: Modulation of cyclic guanosine monophosphate production during Escherichia coli septic shock. Biochem Med Metab Biol 1994, 51:149-155.
26. Salvemini D, Korbut R, Anggard E, Vane J: Immediate release of a nitric oxide-like factor from bovine aortic endothelial cells by Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A 1990, 87:2593-2597.
27. Rees DD, Cellek S, Palmer RMJ, Moncada S: Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun 1990, 173:541-547.
28. Julou-Schaeffer G, Grey GA, Fleming I, Schott C, Parratt JR, Stoclet JC: Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 1990, 259:H1038-H1043.
29. Bernard C, Szekely B, Philip I, Wollman E, Payen D, Tedqui A: Activated macrophages depress the contractility of rabbit carotids via an L-arginine/nitric oxide-dependent effector mechanism connection with amplified cytokine release. J Clin Invest 1992, 89:851-860.
30. Busse R, Mulsch A: Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 1990, 275:87-90.
31. French JF, Lambert LE, Dage RC: Nitric oxide synthase inhibitors inhibit interleukin-1 beta-induced depression of vascular smooth muscle. J Pharmacol Exp Ther 1991, 259:260-262.
32. Schneider F, Lutun P, Hasselman M, Stocklet JC, Temple JD: Methylene blue increases systemic vascular resistance in human septic shock: preliminary observations. Intensive Care Med 1992, 18:309-311.
33. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P: Effects of nitric oxide synthase inhibitor on humans with septic shock. Cardiovasc Res 1994, 28:34-39.
34. Shen W, Xu X, Ochoa M, Zhad G, Wolin MS, Hintze TH: The role of nitric oxide in regulation of oxygen consumption in conscious dogs. Circ Res 1994, 75:1086-1095.
35. Haynes WG, Noon JP, Webb DJ: Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 1993, 11:1375-1380.
36. Cobb JP, Natanson C, Quezado ZM, Hoffman WD, Koev CA, Banks S, et al.: Differential hemodynamic effects of L-NMMA in endotoxemic and normal dogs. Am J Physiol 1995, 268:H1 634-H1642.
37. Kilbourn RG, Gross SS, Jubran A, Adams J, Griffith DW, Levi R, Lodato RF: NG-methyl-L-arginme inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci U SA 1990, 87:3629-3632.
38. Lorente JA, Landin L, Renes E, De Pablo R, Jorge P, Rodena E, Liste D: Role of nitric oxide in the hemodynamic changes of sepsis. Crit Care Med 1993, 21:759-767.
39. Meier-Hellmann A, Reinhart K, Bredle DL, Specht M, Spies CD, Hannemann L: Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 1997, 25:399-404. This study was a well-designed prospective experimentation on the effect of epinephrine on splanchnic perfusion as measured by calculation of intracellular intramucosal gastric pH. Suggests a deleterious effect of epinephrine on splanchnic perfusion.
40. Lowenstein CJ, Dinerman JL, Snyder SH: Nitric oxide: a physiologic messenger. Ann Intern Med 1994, 120:227-237.
41. Perrella MA, Hsieh CW, Lee WS, Shieh S, Tsai JC, Patterson C, et al.: Arrest of endotoxin-induced hypotension by transforming growth factor beta 1. Proc Natl Acad Sci U S A, 1996, 93:2054-2059.
42. Gerlach H, Rossaint R, Rappert D, Falke KJ: Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest 1993, 23:499-502.
43. Lowson SM, Rich GF, McArdle PA, Jaideu J, Morris GN: The response to varying concentrations of inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesth Analg 1996, 82:574-581.
44. Puybasset L, Stewart T, Rouby J-J, Cluzel P, Mourgeon E, Belin MF, et al.: Inhaled nitric oxide reverses the increase in pulmonary vascular resistance induced by permissive hypercapnia in patients with acute respiratory distress syndrome. Anesthesiology 1994, 80:1254-1267.
45. Puybasset L, Rouby J-J, Mourgeon E, Cluzel P, Southil Z, Law-Koune JD, et al.: Factors influencing cardiopulmonary effects of inhaled nitric oxide in acute respiratory failure. Am J Respir Crit Care Med 1995, 152:318-328.
46. Chollet-Martin S, Gatecel C, Kermarrec N, Gougerot-Pocidalo MA, Payen DM: Alveolar neutrophil functions and cytokine levels in patients with adult respiratory distress syndrome during nitric oxide inhalation. Am J Respir Crit Care Med 1996, 153:985-990.
47. Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, et al.: Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Crit Care Med 1998, 26:15-23. First prospective, randomized, double-blind study of inhaled NO in ARDS published in the medical literature. This phase II study supported the lack of toxicity of inhaled NO in ARDS but did not show overall trends in clinical benefit. A post hoc analysis of the 5-ppm subgroup suggested clinical benefit.
48. Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C for the European Study Group of Inhaled Nitric Oxide: Inhalation of nitric oxide in acute lung injury: preliminary results of a European multicenter study [abstract]. Intensive Care Med 1997, 23(suppl 1):S2. This is a European open-label randomized trial of inhaled NO in ARDS that failed to show any evidence of clinical benefit. There was increased incidence of renal replacement therapy in the inhaled NO group. This trend has not been substantiated in the other two large clinical trials. Published thus far in abstract only.
49. Goupe d'Etude sur le NO inhalé au cours de I' ARDS (GENOA). Inhaled NO in ARDS: presentation of a double blind randomized multicentric study [abstract]. Am J Respir Crit Care Med 1996, 153:A590. This is another randomized, prospective study that demonstrated no toxicity but no obvious clinical benefit for inhaled NO. Published thus far in abstract only.
50. Michael JR, Barton RG, Saffle JR, Mone M, Markewitz BA, Hillier K: Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med 1998, 157:1372-1380.
51. Troncy E, Collet J-P, Shapiro S, Guimond J-G, Blair L, Ducruet T, et al.: Inhaled nitric oxide in acute respiratory distress syndrome. Am J Respir Crit Care Med 1998, 157:1483-1488. This is another small randomized study of the use of inhaled NO in ARDS indicating oxygenation benefit over the first 24 hours as the only evident clinical benefit.
52. Date H, Triantafillou AN, Trulock EP, Pohl MS, Cooper JD, Patterson GA: Inhaled nitric oxide reduces human lung allograft dysfunction. J Thorac Cardiovasc Surg 1996, 111:913-919.
53. Adatia I, Lillehei C, Arnold JH, Thompson JE, Palazzo R, Fackler JC, Wessel DL: Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994, 57:1311-1318.
54. Eppinger MJ, Ward PA, Jones ML, Boiling SF, Deeb GM: Disparate effects of nitric oxide on lung ischemia-reperfusion injury. Ann Thorac Surg 1995, 60:1169-1175.
55. Fullerton DA, Jones SD, Jaggers J, Piedalue F, Grover FL, McIntyre RC Jr: Effective control of pulmonary vascular resistance with inhaled nitric oxide after cardiac operation. J Thorac Cardiovasc Surg 1996, 111:753-763.
56. Goldman AP, Delius RE, Deanfield JE, Marcrae DJ: Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operations. Ann Thorac Surg 1995, 60:300-305.
57. Pinelli G, Mertes PM, Carteaux JP, Hubert T, Dopff C, Burtin P, Villemot JP: Inhaled nitric oxide as an adjunct to pulmonary thromboendarterectomy. Ann Thorac Surg 1996, 61:227-229.
58. Estagnaisė P, Le Bourdellė G, Mier L, Coste F, Dreyfuss D: Use of inhaled nitric oxide to reverse flow through a patent foramen ovale during pulmonary embolism. Ann Intern Med 1994, 120:757-759.
59. Semigran MJ, Cockrill BA, Kacmarek R, Thompson BT, Zapol WM, Dec GM, Fifer MA: Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994, 24:982-988.
60. Kavanagh BP, Mouchawar A, Goldsmith J, Pearl RG: Effects of inhaled NO and inhibition of endogenous NO synthesis in oxidant-induced acute lung injury. J Appl Physiol 1994, 76:1324-1329.
61. Guidot D, Repine M, Hybertson B, Repine J: Inhaled nitric oxide prevents neutrophil-mediated, oxygen radical-dependent leak in isolated rat lungs. Am J Physiol 1995, 269(Lung Cell Mol Physiol):L2-L5.
62. Poss W, Timmons O, Farrukh I, Hoidal JR, Michael JR: Inhaled nitric oxide prevents the increase in pulmonary vascular permeability caused by hydrogen peroxide. J Appl Physiol 1995, 79:886-891.
63. Guiterrez HH, Nieves B, Chumley P, Rivera A, Freeman BA: Nitric oxide regulation of superoxide-dependent lung injury: oxidant-protective actions of endogenously administered nitric oxide. Free Radic Biol Med 1996, 21:43-52.
64. Robbins CH, Horowitz S, Merritt TA, Khetter A, Tierney J, Narula P, Davis JM: Recombinant human Superoxide dismutase reduces lung injury caused by inhaled nitric oxide and hyperoxia. Am J Physiol 1997, 272:L903-L907.
65. Hollenberg SM, Cunnion RE: Endothelial and vascular smooth muscle function in sepsis. J Crit Care 1994, 9:262-280.